Background: Microalbuminuria (MA) has emerged as a strong predictor of cardiovascular (CV) events, even in nondiabetic adults. While the mechanisms behind this association remain to be established, most studies suggest that MA is the result of increased vascular leakage denoting endothelial dysfunction associated with early vasculopathy. Objective: To examine if a urine albumin creatinine ratio (UACR) in the microalbuminuric range is related to metabolic markers of CV risk in obese and pre-diabetic youth recruited from an obesity clinic. Methods: MA was defined as a UACR between 2.0 and 20 mg/mmol. Subjects with gross proteinuria (UACR420 mg/mmol) were excluded from the study. Analyses were performed to assess the relationship of MA and markers of CV risk, including body mass index (BMI), % body fat, blood pressure (BP), lipid profile, inflammatory markers, insulin sensitivity indexes and degrees of oral glucose tolerance. MA was also correlated with risk factor constellations unique to the metabolic syndrome, a distinct CV risk entity. Results: Postchallenge alterations in glucose metabolism and overall loss in insulin sensitivity were strongly and positively correlated with the presence of MA (P ¼ 0.002 and 0.01, respectively). Neither the metabolic syndrome nor any of the individual CV risk factors examined were associated with MA. Conclusions: These data suggest that early glucose toxicity, as reflected by postchallenge elevations in plasma glucose even below the diagnostic cutoff for diabetes mellitus may contribute to the presence of MA. Whether MA is equally as predictive of CV disease in youth, as in adulthood, remains to be investigated.
Introduction
Originally introduced as a biomarker of early diabetic nephropathy, large epidemiological trials have indicated that microalbuminuria (MA) is a powerful and independent predictor of all cause mortality and cardiovascular (CV) disease in adults with and without diabetes. [1] [2] [3] [4] [5] [6] [7] Even at levels of albuminuria currently considered normal, rising urinary albumin excretion is associated with increased risk of CV disease. 8, 9 While the mechanism that links MA and CV disease remains unclear, prevailing evidence suggests that glomerular leaking of albumin is a reflection of general vascular damage, therefore denoting preclinical atherosclerosis 10, 11 Indeed, MA is considered a sign of endothelial dysfunction. 12 In light of these reports, it has been suggested that MA screening should be added to the measurement of blood pressure and lipids in the assessment of the CV risk profile in adults. 11 Childhood obesity has reached pandemic proportions, increasing not only in prevalence but also severity over the last decade. 13 The detrimental health consequences are evident in the emergence of 'adult' diseases such as impaired glucose tolerance and type 2 diabetes mellitus in today's children. 14 Of particular concern is the frequently unrecognized presence of the metabolic syndrome, a symptom combination that, in adults, has shown to predict CV mortality. 15 Whether obesity in youth similarly impacts the presence of MA and whether variations in albumin excretion relate to other traditional and nontraditional CV risk factors remains to be determined. This study was undertaken to examine these questions in a large multiethnic cohort of obese children and adolescents without type 2 diabetes mellitus.
Methods

Study population
Subjects were recruited from the Yale Pediatric Obesity Clinic to participate in this study.
To be eligible for inclusion, they had to have a BMI greater than the 97th percentile for age and gender, 16 be in general good health and have normal thyroid function. In order to limit the confounding effects of hyperglycemia and glycosuria on urinary albumin excretion, subjects were excluded if they had diabetes. They were also excluded if they had gross proteinuria (i.e., urinary albumin-to-creatinine ratio 420 mg/mmol). Parent self-report was used to establish race/ ethnicity. The study was approved by the Yale Human Investigation Committee and written parental consent and child assent were obtained prior to commencing the study. The total number of children and adolescents that enrolled in our study were 287. Four subjects were excluded after OGTT revealed type 2 diabetes mellitus. Another six subjects were excluded from the analysis due to the presence of gross proteinuria. The remaining 277 subjects had complete data sets.
Procedures
All procedures were performed in the General Clinical Research Center at the Yale University School of Medicine. Prior to the scheduled study visit, each subject was given a urine collection cup and instructed to collect their first void on the morning of the evaluation and to bring it to the appointment. The subjects were also instructed to refrain from vigorous physical activity for the day leading up to the study date and they were counseled on a balanced weight maintenance diet, avoiding excessive protein or fat for 3 days prior to the study. However, no dietary recall was performed on the day of the study. All children were seen at 0800 hours after a 12 h overnight fast.
Blood pressure was measured in triplicate in a semirecumbent position. The mean of the last two measures was used for the analysis. Percent body fat was measured in all subjects using the bio-impedance technology (Tanita Inc., Arlington Heights, IL, USA). After application of a topical anesthetic cream containing 2.5% lidocaine and 2.5% prilocaine, an intravenous catheter was inserted into an antecubital vein for repeated blood sampling. The catheter was kept patent by slow infusion of normal saline. Before drawing the baseline blood samples, the child was resting comfortably while watching a videotape of his/her choice for 30 min. Baseline blood samples were obtained for measurement of fasting glucose, insulin and lipid profile. Thereafter, the child was asked to drink a flavored glucose drink (Orangedex, Custom Laboratories, Baltimore) containing 1.75 g/kg glucose to a maximum of 75 g. Following glucose ingestion, blood samples were obtained every 30 min for 180 min for measurement of plasma glucose and insulin.
Biochemical analysis
Urine albumin (mg/l) was measured using the Microalbumin System Pack by Boehringer Mannheim R . This assay uses anti-human albumin antibody that reacts specifically with human albumin in urine, forming insoluble antigen-antibody complexes. The turbidity of these complexes is proportional to the albumin concentration, which was measured at a wavelength of 340 nm by an autoanalyzer (model 911 Boehringer Mannheim/Hitachi, Indianapolis, USA). The intra-assay and interassay variation for urine albumin (mg/l) in the low normal range was 7.7 and 8.5%, respectively. The lower limit of detection in this assay was 3 mg/l. A total of 83 subjects had levels below this detection limit.
Urine creatinine (mg/dl) was measured using the Creatinine-S assay from Diagnostic Chemicals Limited R . This method is based on the Jaffe rate reaction in which creatinine reacts with picrate to form a complex at alkaline pH. The rate of absorbance of this complex at 510 nm is directly proportional to the concentration of creatinine in the sample and was measured by autoanalyzer (model 911 Boehringer Mannheim/Hitachi, Indianapolis, USA). Intraassay variation for urinary creatinine values in the low normal range was 1.9% and interassay variation was 1.4%.
Plasma glucose (mg/dl) was measured using a glucose analyzer (Glucose Analyzer II; Beckman Instruments Inc., Fullerton, USA) and lipid levels were analyzed using an autoanalyzer (model 747-200, Roche-Hitachi, Indianapolis). Plasma insulin (mIU/ml) was measured using a radioimmunoassay (Linco Laboratories, St Charles, MO, USA), which has less than 1% crossreactivity with C-peptide and proinsulin. The intra-assay variation for insulin was 4%, and the interassay variation was 10%.
A subset of subjects (n ¼ 252) also had C-reactive protein (CRP). CRP was measured by an ultrasensitive assay (Kamiya Biomedical, Seattle, WA, USA). The intra-assay coefficient of variation was 1.24% and the interassay was 4.2%. Approximately 1/3 of the subjects (85/277) had measures of interleukin 6 (IL-6) using highly sensitive solid-phase ELISA kits (R&D Systems, Minneapolis, MN, USA). The lower limit of detection was 0.1 pg/ml for IL-6 and the intra-assay and interassay coefficient of variation was 3.3 and 3.6%.
Classification
In accordance with the American Diabetes Association guidelines, a subject was classified as having normal glucose tolerance if the 2 h postchallenge glucose was o7.8 mmol/l (o140 mg/dl) and as having impaired glucose tolerance if the 2 h postchallenge blood glucose was between 7.8 and 11.0 mmol/l (140-199 mg/dl). 17 The criteria used to identify pediatric subjects with metabolic syndrome are a modification of the adult criteria from the National Cholesterol Education Program's Adult Treatment Panel and take into account the changing body proportions of the growing child. 15 Therefore, the diagnosis As all of our subjects were obese, they already satisfied one of the five diagnostic criteria of the metabolic syndrome and only required two more of the above criteria to establish the diagnosis.
Urine albumin to creatinine ratio (UACR) was expressed in SI units of mg/mmol. Conversion to mg/mmol was calculated using the following formula:
UACR (mg/mmol) ¼ urine albumin (mg/l)*1000/urine creatinine (mg/dl)*88.4. Subjects were categorized as having a UACR in the microalbuminuric range if the UACR value fell between 2 and 20 mg/mmol. 8 All UACR values below 2 mg/mmol were considered normal. The 83 subjects with urine albumin below the limit of detection were classified as normal UACR as substitution of values for urinary albumin between 0 and 3 mg/l did not elevate UACR above 2 mg/mmol. To assess the subjects' insulin sensitivity, the Composite Whole Body Insulin Sensitivity Index (WBISI) was applied. The WBISI, originally described by Matsuda and DeFronzo, 18 was recently validated for its application in children. 15 The calculation of the WBISI is based on the mean values of insulin (mIU/ml) and glucose (mg/dl) obtained every 30 min during a 180 min OGTT and the corresponding fasting values. The calculation is performed as follows: WBISI ¼ 10 000 divided by the square root of (fasting glucose * fasting insulin) (mean glucose * mean insulin). Insulin resistance was determined by the commonly used homeostatic model assessment (HOMA-IR), a simple mathematical model requiring only a fasting blood of insulin and glucose. 19 
Statistics
Unless otherwise noted, all data are expressed as means with 95% confidence intervals or frequencies (%) as appropriate. Instead of absolute BMI values, all analyses were performed using the BMI-z score in which one unit is equivalent to one standard deviation above the average age-and sex-adjusted normal standards. Positively skewed variables were logtransformed to meet assumptions of statistical tests. Geometric means were used to describe these variables. Simple comparisons of demographic and anthropometric variables were made with t-tests and w 2 tests. Multiple linear and logistic regressions were used to compare UACR category with CV and metabolic factors while adjusting for age, sex, BMI z-score and race/ethnicity.
Results
MA was present in 10.1% (28/277) of our subjects. When the cohort was categorized by level of UACR (normal UACR vs UACR in the microalbuminuric range), there were no significant differences between the two groups in terms of the anthropometrical and common CV risk factors such as BMI, systolic blood pressure and dyslipidemia (see Tables 1  and Table 2 ). In contrast, we found marked differences in both the plasma glucose and insulin responses to the OGTT between the two groups. As shown in Figure 1a and b, subjects with MA displayed significantly higher plasma glucose and insulin levels during the OGTT, even after adjusting for possible confounders such as BMI, age, gender and ethnicity. As a result of these higher plasma glucose and insulin levels, both the area under the curve for glucose (AUC for glucose) and insulin (AUC for insulin) were significantly greater in the subjects with MA compared with those with normal UACR. While fasting insulin levels were somewhat more elevated (yet not statistically significant) in subjects with MA, fasting blood glucose levels were clearly not associated with the presence of MA in this cohort (Table 2) .
When our cohort was analyzed for any risk factor constellation that would constitute the metabolic syndrome, we did not find a correlation between the presence of metabolic syndrome and microalbuminuria. This can be attributed to the fact that impaired glucose tolerance was not Microalbuminuria in obese youth TS Burgert et al one of the predominant factors composing the metabolic syndrome in our cohort. In addition to obesity (100% if subjects), the second most common criterion that was met by our subjects was elevated blood pressure (79% of subjects with metabolic syndrome) and low HDL (67% of subjects with metabolic syndrome). To test the relationship between the diagnostically/ clinically used 120 min postchallenge glucose level and the presence of MA, we stratified the cohort according to quintiles of plasma glucose at the 120 min time point during the OGTT. It is remarkable that the presence of MA increased as the 120 min plasma glucose rose (Figure 2 ). Of particular note is that our analysis was able to show a trend in the relationship between the 120 min postchallenge glucose, even though the majority of subjects had glucose levels in so-called 'normal' range of glucose tolerance.
In line with our findings of an association between fasting/ postchallenge insulin and postchallenge glucose excursions with MA is that the insulin sensitivity index WBISI was the only other risk factor that cosegregated with higher UACR levels. All analyses of metabolic and CV risk factors were controlled for BMI, sex, ethnicity and age. remains controversial as to which of the potential vascular toxins gives rise to MA. [23] [24] [25] Having demonstrated that MA is quite common in obese children and adolescents, we were particularly interested in determining how it relates to other CV risk factors in this young cohort. The major findings of our study were the strong positive correlation between the presence of MA and AUC for glucose and insulin, which in turn was linked to an overall reduction in insulin sensitivity as measured by WBISI. This relationship was further strengthened when the analysis was controlled for age, sex, race/ethnic background and BMI. The link between CV mortality, MA and type 2 diabetes 26 Figure 2 Relationship between % of subjects with a UACR in the microalbuminuric range and the 120 min plasma glucose levels after a standard oral glucose load. The dashed vertical line between the third and the fourth glucose quintile denotes the clinical threshold for the diagnosis of impaired glucose tolerance. *Adjusted for age, sex, BMI z-score and race/ ethnicity.
Microalbuminuria in obese youth TS Burgert et al and was more common in subjects with impaired glucose tolerance. 30 The Framingham Offspring study further confirmed that MA was associated with sub-diabetic levels of glycemia before the development of T2DM and CVD. 31 In this context, it is noteworthy that even within normal glucose tolerance there appears to be a linear relationship between an adult's glycemic milieu and the degree of coronary artery disease. 32, 33 While there is no data in regards to the predictive value of assessing urinary albumin excretion in obese youth, Pediatric obesity research has become increasingly aware of UACR as a potential marker forecasting CV health. In fact, a European study just reported on urinary albumin levels in a group of young obese subjects with striking parallels to our observations. 34 In this study, the authors denote that while urinary albumin excretion is higher in obese than in lean subjects, BMI per se did not contribute to the presence of higher urinary albumin secretion once obese and lean subjects were analyzed separately. Therefore, metabolic consequences of obesity and not obesity itself may be the driving forces behind urinary albumin excretion. Indeed, the authors propose that in obese youth, higher UACR may be determined by pre-diabetic alterations in glucose metabolism as well as the presence of insulin resistance. 34 In our large multiethnic study cohort, we were able to additionally demonstrate that the prevalence of MA increased as plasma glucose values climbed through the 'normal range' into the impaired range of glucose tolerance, denoting that the effect of glycemia may be continuous as opposed to a threshold parameter. In stark contrast to postchallenge glucose excursions, we did not observe a relationship between fasting glucose and the presence of MA in our study. Assuming that MA serves as an indicator of CV risk, it is of note that in adults postchallenge derangement of glucose metabolism predicts CV mortality better than any abnormalities in fasting glucose levels. 17 In fact, a recent clinical trial in adults demonstrated that, in subjects with impaired glucose tolerance, pharmacological targeting of postchallenge glycemia alone prevented CV events by 49%. 35 A potential mechanism linking short lived states of glycemia to vascular health is the 'oxidative stress theory', where the production of superoxide anions such as peroxynitrite leads to endothelial dysfunction. 36 In support of this premise, a recent clinical study demonstrated that an amelioration of postprandial glucose excursions in subjects with type 1 diabetes is linked to a reduction in oxidative stress as assessed by reduced plasma nitrotyrosine levels. 37 In interpreting our data, we therefore hypothesize that in obese, otherwise healthy adolescents, recurrent states of postprandial glycemia increase oxidative stress on the vasculature, leading to endothelial dysfunction and MA. Unfortunately, we did not measure specific indicators of oxidative stress, which would have been helpful in supporting our hypothesis. In our study, reduced insulin sensitivity as assessed by the WBISI was also associated with the presence of MA. The WBISI is a composite index of insulin sensitivity, where fasting and postchallenge glucose and insulin values feed into the equation. Its applicability to pediatric subjects was recently validated against the M-value obtained from the euglycemic-hyperinsulinemic clamp. 38 Studies in adults with type 2 diabetes have demonstrated that insulin resistance may contribute to micro and macrovascular disease. 39, 40 In a group of Japanese subjects with type 2 diabetes, insulin resistance was associated with MA and direct measures of endothelial function. 41 An interesting aspect of our study was that HOMA, a more commonly used measure of insulin sensitivity based on fasting glucose and insulin levels alone, was not associated with MA. We therefore interpret our WBISI association with caution, realizing that postchallenge glucose excursions are an integral part of the WBISI calculation and that insulin resistance will always be intimately linked to postchallenge glucose excursions in most obese subjects. We further hypothesize that, while insulin resistance is the prerequisite for postchallenge glycemia in our cohort of obese youth, it may be glycemia rather than insulin resistance driving the urinary albumin excretion. Metabolic syndrome, a variable combination of specific CV and metabolic risk factors, leads to premature CV mortality in adults and its presence in children is linked to obesity. 15 In our study, the presence of metabolic syndrome in youth was not linked to MA, even though they are both very strong predictors of CV disease. In terms of interpreting our findings, we conclude that, while all criteria are deemed equal in terms of defining metabolic syndrome, some may be more 'equal' than others in terms of CV health. This may explain why African American adult men, even though they have a lower incidence of metabolic syndrome, 42 still have a higher risk of CV disease. This population may be more susceptible to some form of impaired glucose tolerance but at the same time be lacking the other components of the metabolic syndrome. Another unexpected finding of our analyses was that systolic hypertension did not segregate with MA. However, there are a few reports that suggest that the presence of MA further and independently increases the risk of CV disease beyond that of hypertension itself. [43] [44] [45] For this reason it has been argued that additional factors in the hypertensive patient, such as insulin resistance, could be contributing to the development of MA. 30, [46] [47] [48] [49] Fittingly, our data imply that worsening of insulin resistance as assessed by WBISI may contribute to MA prior to its effect on systolic blood pressure. However, since 24-h ambulatory blood pressure measurements were not performed in this study, we may have underestimated the degree of blood pressure elevation in this cohort as well as a potential correlation with MA. One of the limitations of our study is that we only have one spot UACR per child, instead of timed collections. However, several prior reports indicate that early morning urines provide a good estimate of the 24 h excretion rate. [50] [51] [52] We also did not control for the inherent day-to-day variability of urine albumin excretion by assessing several Microalbuminuria in obese youth TS Burgert et al first morning voids in the same subject and averaging the results, a practice that has evolved from diagnosing incipient nephropathy. Then again the purpose of this study was to look at general trends in a population as opposed to determining an individual's risk of developing nephropathy. By using the first morning void we aimed to control for several of the potential confounders that may affect urinary albumin excretion such as diurnal variation, intense physical activity or acute water consumption. Obesity has also been reported as a confounder in the assessment of UACR, mainly by being associated with reversible nephrotric syndrome. Therefore, we excluded all subjects with gross proteinuria in order to control for obesity-induced segmental glomerulosclerosis. 53 Furthermore, a recent study in nondiabetic and nonhypertensive adults found that BMI did not contribute to the presence of MA. 54 In summary, the present study was undertaken in children to assess if the occurrence of urinary microalbumin in obese youth would highlight early shifts in the metabolic equilibrium. Assuming that an elevated UACR is representative of poor vascular health, our findings suggest that even slight abnormalities in glucose metabolism may be a driving force in early vascular damage in the toxic environment of pediatric obesity. The fact that even subtle changes in glucose metabolism segregate with the presence of MA implies that improving glycemia even within the so-called 'normal' range may reduce the risk of looming CV disease. As it has been suggested for adults, 55, 56 elevated levels of UACR may also become an approachable treatment target in the framework of pediatric obesity perhaps responsive to lifestyle intervention or pharmacotherapy that is directed at improving insulin sensitivity and postchallenge glucose metabolism. Further studies are urgently needed in this area of metabolic/CV health in obese youth.
